Overview

Tricuspid valve regurgitation is a type of heart valve disease. The valve between the two right heart chambers doesn't close as it should. This causes blood to flow backward through the valve. Blood moves from the lower right heart chamber, called the right ventricle, into the upper right chamber, called the right atrium. It may be described as a leaky tricuspid valve and is one type of tricuspid valve disease. The condition also may be called tricuspid regurgitation or tricuspid insufficiency.

If the valve leak is severe, forward blood flow may decrease and pressure may rise in the right atrium and veins.

Some people are born with heart valve disease that leads to tricuspid valve regurgitation. This is called congenital heart valve disease. But tricuspid valve regurgitation also may happen later in life due to infections, pacemaker implantation issues or other health conditions.

Mild and even moderate tricuspid valve regurgitation may not cause symptoms or need treatment. If the condition is severe and causes symptoms, medicine or a procedure to repair or replace the valve may be needed.

A leaky tricuspid valve

The tricuspid valve's job is to allow blood flowing into the heart from the body to flow to the right ventricle where it's pumped to the lungs for oxygen. If the tricuspid valve is leaky, blood can flow backwards, causing the heart to pump harder. Over time, the heart becomes enlarged and functions poorly.

Valve conditions in children and Ebstein anomaly

Types

The main types of tricuspid valve regurgitation are primary, secondary and device related. Primary regurgitation mainly affects the tricuspid valve's leaflets or supporting structures. Secondary regurgitation happens when changes to the right atrium, right ventricle or ring around the valve keep the tricuspid valve from closing completely. Device-related regurgitation may happen when a wire, called a lead, from a pacemaker or defibrillator crosses the tricuspid valve.

Symptoms

Tricuspid valve regurgitation may cause no symptoms. Some people with severe disease may not have symptoms for years. Your healthcare team may find the condition when doing echocardiograms for another reason.

Symptoms of tricuspid valve regurgitation may include:

  • Feeling very tired.
  • Shortness of breath with activity.
  • A rapid or pounding heartbeat.
  • Pounding or pulsing feeling in the neck.
  • Bulging neck veins.
  • Swelling in the belly or legs.

Symptoms may be caused by the tricuspid valve leak, right-sided heart failure or another heart condition.

When to seek care

Make an appointment if you get tired very easily or feel short of breath with activity. You may need to see a doctor trained in heart conditions, called a cardiologist.

Causes

To understand the causes of tricuspid valve regurgitation, it may help to know how the heart and heart valves typically work.

A typical heart has four chambers.

  • The two upper chambers, called the atria, receive blood.
  • The two lower chambers, called the ventricles, pump blood.

Four valves open and close to keep blood flowing in the correct direction. These heart valves are:

  • Aortic valve.
  • Mitral valve.
  • Tricuspid valve.
  • Pulmonary valve.

The tricuspid valve is between the heart's two right chambers. It has three thin flaps of tissue, called cusps or leaflets. These flaps open to let blood move from the upper right chamber to the lower right chamber. The valve flaps then close tightly so blood doesn't flow backward.

In tricuspid valve regurgitation, the tricuspid valve doesn't close tightly. So, blood may leak backward from the lower right heart chamber, called the right ventricle, into the upper right heart chamber, called the right atrium.

Tricuspid valve regurgitation can happen with mitral valve regurgitation. When more than one valve is involved, an echocardiogram helps your care team understand what is happening with each valve and the effects on heart-chamber size and pumping function.

Mitral valve disease also may raise pressure in the main veins in the lungs and contribute to secondary tricuspid regurgitation.

Causes of tricuspid valve regurgitation include:

  • A heart condition you're born with, also called a congenital heart defect. Some congenital heart defects affect the shape of the tricuspid valve and how it works. Ebstein anomaly is a rare congenital heart defect that is an important congenital cause of tricuspid valve regurgitation in children. In this condition, the tricuspid valve does not form as it should. The valve forms lower than expected in the right ventricle and may not close completely.
  • Marfan syndrome. Changes in genes cause this condition. Marfan syndrome and other connective tissue disorders affect the fibers that support and anchor the organs and other structures in the body. It's sometimes related to tricuspid valve regurgitation.
  • Rheumatic fever. This condition is a complication of a strep infection that can affect the heart. When this happens, it's called rheumatic heart valve disease. Rheumatic tricuspid valve regurgitation can happen from rheumatic valve damage and often happens with mitral or aortic valve disease. Nonrheumatic tricuspid valve regurgitation means the leak is not caused by rheumatic fever.
  • Infection of the lining of the heart and heart valves, called infective endocarditis. Infective endocarditis can damage the tricuspid valve. Injection drug use can raise the risk of infective endocarditis.
  • Carcinoid syndrome. Carcinoid syndrome happens when a tumor produces substances that may lead to changes in heart valves. Carcinoid syndrome can lead to carcinoid heart disease. This disease damages heart valves, most commonly the tricuspid and pulmonary valves.
  • Chest injury. A blunt injury to the chest, such as from a car accident, may cause damage that leads to tricuspid valve regurgitation.

Some tests or treatments for other conditions can affect the tricuspid valve. These include:

  • Pacemaker or other heart device leads. Tricuspid valve regurgitation might happen if wires, called leads, from a pacemaker or defibrillator cross the tricuspid valve and affect the leaflet movement, change the shape of the right ventricle or cause scarring of the valve leaflets.
  • Heart biopsy, also called an endomyocardial biopsy. Heart valve damage can sometimes happen when the care team removes a small amount of heart muscle tissue for testing.
  • Radiation therapy. Radiation therapy to treat cancer in the chest area can damage the tricuspid valve and lead to tricuspid valve regurgitation.
  • Certain medicines. Use of some medicines has been linked with heart valve damage. The link depends on the specific medicine, the dose and how long you've used it. Ask your care team if any of your current or previous medicines may affect the heart valves.

Risk factors

A risk factor is something that raises your chance of developing a health condition.

Things that can raise the risk of tricuspid valve regurgitation include:

  • An irregular heartbeat called atrial fibrillation (AFib). Long-lasting atrial fibrillation can enlarge the upper right heart chamber and the ring around the tricuspid valve. This can keep the valve from closing and lead to secondary tricuspid valve regurgitation.
  • Being born with a heart condition, called a congenital heart defect. A congenital heart defect may affect the structure or position of the tricuspid valve.
  • Damage to the right heart muscle. A heart attack or other condition that can affect the lower right heart chamber or the muscles supporting the tricuspid valve can lead to tricuspid valve regurgitation.
  • Heart failure on the right side or another condition that makes the lower right heart chamber larger. Enlargement of the right ventricle or the tricuspid valve ring can keep the valve leaflets from closing completely. This can cause blood to leak backward. This is called secondary tricuspid regurgitation. A severe leak can add stress to the heart from the extra volume, make the right ventricle larger, and weaken the heart muscle over time.
  • High blood pressure in the lungs, also called pulmonary hypertension. Pulmonary hypertension can increase pressure in the right ventricle. This can cause the right ventricle to enlarge and keep the tricuspid valve leaflets from closing. This can cause or worsen secondary tricuspid regurgitation. Severe regurgitation also can worsen the enlarged right side of the heart.
  • A history of infective endocarditis. This infection can damage the inner lining and valves in the heart and can damage the tricuspid valve.
  • History of radiation therapy to the chest area. Radiation can affect the tricuspid valve and cause damage, which can lead to regurgitation.

Complications

Complications of tricuspid valve regurgitation may depend on how severe the condition is. Possible complications include:

  • An irregular and often rapid heartbeat, called atrial fibrillation (AFib). Some people with severe tricuspid valve regurgitation also have this common heart rhythm condition. Long-lasting atrial fibrillation may enlarge the right atrium and tricuspid valve ring, which can worsen the leak. Severe tricuspid valve regurgitation also may enlarge the right atrium and contribute to an irregular rhythm in the atria.
  • Right-sided heart failure and effects on the liver or kidneys. Severe tricuspid valve regurgitation can raise pressure in the right atrium and veins. The right ventricle can enlarge and weaken. This can reduce forward blood flow and cause heart failure on the right side of the heart. Heart failure is when the heart muscle doesn't pump blood as well as it should. Fluid may build up in the legs or belly. Ongoing pressure in the veins and fluid buildup may affect the kidneys and liver.

Sept. 23, 2026

Living with tricuspid valve regurgitation?

Connect with others like you for support and answers to your questions in the Heart & Blood Health support group on Mayo Clinic Connect, a patient community.

Heart & Blood Health Discussions

teatime
Stopping Carvedilol (Coreg): When will the effects wear off?

419 Replies Sat, Sep 26, 2026

mcphee
High Coronary Calcium Score: How do others feel emotionally?

697 Replies Thu, Sep 17, 2026

pop77
Living with high calcium score

118 Replies Sat, Sep 12, 2026

See more discussions
  1. Ferri FF. Tricuspid regurgitation. In: Ferri's Clinical Advisor 2024. Elsevier; 2024. https://www.clinicalkey.com. Accessed Aug. 31, 2026.
  2. Otto CM, et al. 2020 ACC/AHA Guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2021; doi:10.1016/j.jacc.2020.11.018.
  3. Otto CM. Etiology, clinical features, and evaluation of tricuspid regurgitation. https://www.uptodate.com/contents/search. Accessed Aug. 31, 2026.
  4. Phillips KA, et al. Contemporary early postoperative cone repair outcomes for patients with Ebstein anomaly. Mayo Clinic Proceedings. 2023; doi:10.1016/j.mayocp.2022.06.009.
  5. Stress and heart health. American Heart Association. https://www.heart.org/en/healthy-living/healthy-lifestyle/stress-management/stress-and-heart-health. Accessed May 28, 2026.
  6. Libby P, et al., eds. Tricuspid, pulmonic, and multivalvular disease. In: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 12th ed. Elsevier; 2022. https://www.clinicalkey.com. Accessed Aug. 31, 2026.
  7. Patlolla SH, et al. Incidence and burden of tricuspid regurgitation in patients with atrial fibrillation. Journal of the American College of Cardiology. 2022; doi:10.1016/j.jacc.2022.09.045.
  8. Otto CM. Management and prognosis of tricuspid regurgitation. https://www.uptodate.com/contents/search. Accessed Aug. 31, 2026.
  9. Life's essential 8. American Heart Association. https://www.heart.org/en/healthy-living/healthy-lifestyle/lifes-essential-8/lifes-essential-8-fact-sheet. Accessed May 28, 2026.
  10. AskMayoExpert. Tricuspid regurgitation (adults). Mayo Clinic; 2025.
  11. Silversides C, et al. Pregnancy and valve disease. https://www.uptodate.com/contents/search. Accessed Aug. 31, 2026.
  12. Edwards EVOQUE Tricuspid Valve Replacement System — P230013. U.S. Food and Drug Administration. https://www.fda.gov/medical-devices/recently-approved-devices/edwards-evoque-tricuspid-valve-replacement-system-p230013. Accessed Aug. 28, 2026.
  13. Tricuspid valve repair and tricuspid valve replacement. Mayo Clinic. https://www.mayoclinic.org/tests-procedures/tricuspid-valve-repair-tricuspid-valve-replacement/about/pac-20385087. Accessed Sept. 3, 2026.
  14. Lloyd-Jones DM, et al. Life's essential 8: Updating and enhancing the American Heart Association's construct of cardiovascular health: A presidential advisory from the American Heart Association. Circulation. 2022; doi:10.1161/CIR.0000000000001078.
  15. Wilson WR, et al. Prevention of Viridans group streptococcal infective endocarditis: A scientific statement from the American Heart Association. Circulation. 2021; doi:10.1161/CIR.0000000000000969.
  16. Rehan ST, et al. Transcatheter edge-to-edge repair for tricuspid regurgitation: A systematic review and meta-analysis. Current Problems in Cardiology. 2024; doi:10.1016/j.cpcardiol.2023.102055.
  17. Tang GHL, et al. Tricuspid transcatheter edge-to-edge repair for severe tricuspid regurgitation: 1-year outcomes from the TRILUMINATE randomized cohort. Journal of the American College of Cardiology. 2025; doi:10.1016/j.jacc.2024.10.086.
  18. Heart valve disease. Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/heart-valve-disease/diagnosis-treatment/drc-20353732. Accessed May 28, 2026.
  19. Fortier JH, et al. Drug-associated valvular heart diseases and serotonin-related pathways: A meta-analysis. Heart. 2019; doi:10.1136/heartjnl-2018-314403.
  20. Balata M, et al. Comparative analysis of MitraClip/TriClip and PASCAL in transcatheter tricuspid valve repair for tricuspid regurgitation: A systematic review and meta-analysis. BMC Cardiovascular Disorders. 2024; doi:10.1186/s12872-024-04201-6.
  21. Risk factor. National Cancer Institute. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/risk-factor. Accessed May 28, 2026.
  22. O'Gara PT, et al. 10 issues for the clinician in tricuspid regurgitation evaluation and management: 2025 ACC Expert Consensus Decision Pathway. Journal of the American College of Cardiology. 2026; doi:10.1016/j.jacc.2025.07.002.
  23. Mukherjee M, et al. Guidelines for the echocardiographic assessment of the right heart in adults and special considerations in pulmonary hypertension: Recommendations from the American Society of Echocardiography. Journal of the American Society of Echocardiography. 2025; doi:10.1016/j.echo.2025.01.006.
  24. Adamo M, et al. Epidemiology, pathophysiology, diagnosis and management of chronic right-sided heart failure and tricuspid regurgitation: A clinical consensus statement of the Heart Failure Association and the European Association of Percutaneous Cardiovascular Interventions of the ESC. European Journal of Heart Failure. 2024; doi:10.1002/ejhf.3106.
  25. Kucuk HO, et al. Natural history of tricuspid valve regurgitation: Understanding the limitations of medical therapy. Mayo Clinic Proceedings. 2025; doi:10.1016/j.mayocp.2024.09.022.
  26. Arteagoitia Bolumburu A, et al. Determinants of tricuspid regurgitation progression and its implications for adequate management. JACC: Cardiovascular Imaging. 2024; doi:10.1016/j.jcmg.2023.10.006.
  27. Deharo JC, et al. Management of patients with transvalvular right ventricular leads undergoing transcatheter tricuspid valve interventions: A scientific statement of the European Heart Rhythm Association and the European Association of Percutaneous Cardiovascular Interventions of the ESC endorsed by the Heart Rhythm Society, the Asian Pacific Heart Rhythm Society and the Canadian Heart Rhythm Society. Europace. 2025; doi:10.1093/europace/euaf061.
  28. Chick W, et al. A systematic review and meta-analysis of the clinical outcomes of isolated tricuspid valve surgery. American Journal of Cardiology. 2023; doi:10.1016/j.amjcard.2023.07.006.
  29. Kar S, et al. Two-year outcomes of transcatheter edge-to-edge repair for severe tricuspid regurgitation: The TRILUMINATE Pivotal randomized controlled trial. Circulation. 2025; doi:10.1161/CIRCULATIONAHA.125.074536.
  30. O'Gara PT, et al. Operator and institutional recommendations and requirements for tricuspid interventions: 2026 ACC/AHA/ASE/HRS/STS expert consensus systems of care document. Journal of the American College of Cardiology. 2026; doi:10.1016/j.jacc.2026.02.5069.
  31. De Backer J, et al. 2025 ESC guidelines for the management of cardiovascular disease and pregnancy. European Heart Journal. 2025; doi:10.1093/eurheartj/ehaf193.
  32. Expert Consensus Panel, et al. The American Association for Thoracic Surgery 2025 expert consensus document: Management of Ebstein anomaly in children and adults. Journal of Thoracic and Cardiovascular Surgery. 2025; doi:10.1016/j.jtcvs.2025.03.014.
  33. 2025 ACC/AHA/HRS/ISACHD/SCAI guideline for the management of adults with congenital heart disease. Circulation. 2026; doi:10.1161/CIR.0000000000001402.
  34. Hammad A, et al. Association between ergot-derived dopamine agonists and valvular heart disease: A systematic review and meta-analysis. Cardiology in Review. 2026; doi:10.1097/CRD.0000000000001387.
  35. TriClip G4 System — P230007. U.S. Food and Drug Administration. https://www.fda.gov/medical-devices/recently-approved-devices/triclip-g4-system-p230007. Accessed Aug. 28, 2026.
  36. Medical review (expert opinion). Mayo Clinic. Sept. 16, 2026.